Acquisitions, Investments, and Licenses (Tables)
|
9 Months Ended |
Sep. 30, 2012
|
Business Acquisition [Line Items] |
|
Maximum exposure of investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Dollars in thousands)
Investee Name
|
|
Year Acquired |
|
|
Accounting Method
|
|
Ownership September 30, 2012 |
|
|
Investment |
|
|
Underlying equity in net assets |
|
Sorrento
|
|
|
2009 |
|
|
Equity method |
|
|
19 |
% |
|
$ |
2,300 |
|
|
$ |
1,596 |
|
Cocrystal
|
|
|
2009 |
|
|
Equity method |
|
|
16 |
% |
|
|
2,500 |
|
|
|
1,012 |
|
Neovasc
|
|
|
2011 |
|
|
Equity method, cost (warrants) |
|
|
4 |
% |
|
|
2,013 |
|
|
|
146 |
|
Fabrus
|
|
|
2010 |
|
|
VIE, equity method |
|
|
13 |
% |
|
|
650 |
|
|
|
53 |
|
BZNE common stock
|
|
|
2012 |
|
|
VIE, equity method |
|
|
12 |
% |
|
|
1,276 |
|
|
|
(9 |
) |
Less: accumulated losses in investees
|
|
|
|
|
|
|
(4,115 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total carrying value of equity method investees
|
|
|
|
|
|
|
4,624 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BZNE Note and conversion feature
|
|
|
2012 |
|
|
VIE, investment available for sale |
|
|
N/A |
|
|
|
1,700 |
|
|
|
|
|
ChromaDex
|
|
|
2012 |
|
|
Investment, available for sale |
|
|
1 |
% |
|
|
1,000 |
|
|
|
|
|
Neovasc options
|
|
|
2011 |
|
|
Investment, available for sale |
|
|
N/A |
|
|
|
925 |
|
|
|
|
|
TESARO
|
|
|
2010 |
|
|
Investment, available for sale |
|
|
2 |
% |
|
|
731 |
|
|
|
|
|
Plus: unrealized gains on investments, options and warrants, net
|
|
|
|
|
|
|
6,018 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total carrying value of investments, available for sale
|
|
|
|
|
|
|
10,374 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
$ |
14,998 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ALS acquisition [Member]
|
|
Business Acquisition [Line Items] |
|
Estimated fair value of the net assets acquired and liabilities assumed at the dates of acquisition |
|
|
|
|
|
(In thousands)
|
|
|
|
Current assets (includes cash of $230)
|
|
$ |
9,134 |
|
Intangible assets:
|
|
|
|
|
Customer relationships
|
|
|
436 |
|
Technology
|
|
|
5,437 |
|
In-process research and development
|
|
|
1,459 |
|
Product registrations
|
|
|
5,230 |
|
Covenants not to compete
|
|
|
187 |
|
Tradename
|
|
|
1,029 |
|
|
|
|
|
|
Total intangible assets
|
|
|
13,778 |
|
Goodwill
|
|
|
8,520 |
|
Plant and equipment
|
|
|
7,229 |
|
Other assets
|
|
|
611 |
|
Accounts payable and accrued expenses
|
|
|
(3,667 |
) |
Deferred tax liability
|
|
|
(3,169 |
) |
Deferred payment
|
|
|
(7,755 |
) |
Debt assumed
|
|
|
(7,829 |
) |
Contingent consideration
|
|
|
(1,197 |
) |
|
|
|
|
|
Total purchase price
|
|
$ |
15,655 |
|
|
|
|
|
|
|
FineTech acquisition [Member]
|
|
Business Acquisition [Line Items] |
|
Estimated fair value of the net assets acquired and liabilities assumed at the dates of acquisition |
|
|
|
|
|
(In thousands)
|
|
|
|
Current assets (including cash of $2,000)
|
|
$ |
3,358 |
|
Intangible assets:
|
|
|
|
|
Customer relationships
|
|
|
14,200 |
|
Technology
|
|
|
2,700 |
|
Covenants not to compete
|
|
|
1,500 |
|
Tradename
|
|
|
400 |
|
|
|
|
|
|
Total intangible assets
|
|
|
18,800 |
|
Goodwill
|
|
|
11,623 |
|
Plant and equipment
|
|
|
1,358 |
|
Other assets
|
|
|
1,154 |
|
Accounts payable and accrued expenses
|
|
|
(910 |
) |
Deferred tax liability
|
|
|
(2,457 |
) |
Contingent consideration
|
|
|
(4,747 |
) |
|
|
|
|
|
Total purchase price
|
|
$ |
28,179 |
|
|
|
|
|
|
|
Claros Diagnostics acquisition [Member]
|
|
Business Acquisition [Line Items] |
|
Estimated fair value of the net assets acquired and liabilities assumed at the dates of acquisition |
|
|
|
|
|
(In thousands)
|
|
|
|
Current assets (including cash of $351)
|
|
$ |
378 |
|
Technology
|
|
|
44,400 |
|
Goodwill
|
|
|
17,977 |
|
Equipment
|
|
|
333 |
|
Other assets
|
|
|
18 |
|
Accounts payable and accrued expenses
|
|
|
(655 |
) |
Deferred tax liability
|
|
|
(17,254 |
) |
Contingent consideration
|
|
|
(12,745 |
) |
|
|
|
|
|
Total purchase price
|
|
$ |
32,452 |
|
|
|
|
|
|
|